Two Novel Mosquitocidal Peptides Isolated from the Venom of the Bahia Scarlet Tarantula (Lasiodora klugi)

Toxins (Basel). 2023 Jun 27;15(7):418. doi: 10.3390/toxins15070418.

Abstract

Effective control of diseases transmitted by Aedes aegypti is primarily achieved through vector control by chemical insecticides. However, the emergence of insecticide resistance in A. aegypti undermines current control efforts. Arachnid venoms are rich in toxins with activity against dipteran insects and we therefore employed a panel of 41 spider and 9 scorpion venoms to screen for mosquitocidal toxins. Using an assay-guided fractionation approach, we isolated two peptides from the venom of the tarantula Lasiodora klugi with activity against adult A. aegypti. The isolated peptides were named U-TRTX-Lk1a and U-TRTX-Lk2a and comprised 41 and 49 residues with monoisotopic masses of 4687.02 Da and 5718.88 Da, respectively. U-TRTX-Lk1a exhibited an LD50 of 38.3 pmol/g when injected into A. aegypti and its modeled structure conformed to the inhibitor cystine knot motif. U-TRTX-Lk2a has an LD50 of 45.4 pmol/g against adult A. aegypti and its predicted structure conforms to the disulfide-directed β-hairpin motif. These spider-venom peptides represent potential leads for the development of novel control agents for A. aegypti.

Keywords: Aedes aegypti; Lasiodora klugi; disulfide-directed β-hairpin; inhibitor cystine knot; insecticidal toxin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brazil
  • Insecta
  • Mosquito Vectors
  • Peptides / pharmacology
  • Spider Venoms* / chemistry
  • Spider Venoms* / toxicity
  • Venoms* / pharmacology

Substances

  • Venoms
  • Peptides
  • Spider Venoms

Grants and funding

This research was funded by the International Foundation for Science Sweden (I-1-F-6130-1) and the Institute for Molecular Bioscience, The University of Queensland, Australia. VH was supported by an Australian Research Council (ARC) Future Fellowship (FT190100482). AAW was supported by the ARC through Discovery Project DP200102867; IV was supported by a National Health and Medical Research Council (NHMRC) Investigator grant 2017086; GFK was supported by an NHMRC Principal Research Fellowship APP1136889; and AAW, SG, SAN, and GFK were supported as part of the ARC Centre of Excellence for Innovations in Peptide and Protein Science CE200100012.